Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results

被引：8

作者：

Ogdie, Alexis ^{[1
,2
]}

Liu, Mei ^{[3
]}

Glynn, Meghan ^{[3
]}

Emeanuru, Kelechi ^{[3
]}

Harrold, Leslie R. ^{[4
]}

Richter, Sven ^{[5
]}

Guerette, Benoit ^{[5
]}

Mease, Philip J. ^{[6
,7
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA

[3] Corrona LLC, Waltham, MA USA

[4] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA

[5] Amgen Inc, Global Med Affairs, Thousand Oaks, CA 91320 USA

[6] Univ Washington, Sch Med, Div Rheumatol Clin Res, Swedish Med Ctr,Providence St Joseph Hlth, Seattle, WA USA

[7] Univ Washington, Sch Med, Div Rheumatol, Seattle, WA USA

来源：

JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 05期

关键词：

arthritis; methotrexate; psoriatic arthritis; TNF receptors; RECOMMENDATIONS; DISEASE; PSA;

D O I：

10.3899/jrheum.191209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA). Methods. Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included. Results. In total, 150 patients initiated rnonotherapy (aprernilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators. Conclusion. Findings suggest aprernilast monotherapy is an effective option for patients with oligoarticular PsA.

引用

页码：693 / 697

页数：5

共 50 条

[41] Psoriatic arthritis risk in psoriasis patients in the Corrona® Psoriasis Registry
Ogdie, A.
Harrison, R. W.
McLean, R. R.
Lin, T.
Lebwohl, M.
Strober, B.
Zhuo, J.
Patel, V.
Mease, P.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S53 - S53
[42] THE EFFECT OF DACTYLITIS AND ENTHESITIS ON DISEASE BURDEN IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE CORRONA REGISTRY
Mease, P.
Saunders, K.
Bolge, S.
Bolce, R.
Decktor, D.
Reed, G.
Greenberg, J.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 577 - 577
[43] CHARACTERISTICS OF A US PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS COHORT: BASELINE DATA FROM THE CORRONA PSA/SPA REGISTRY
Mease, P. J.
Etzel, C. J.
Kremer, J. M.
Deveikis, S.
Li, Y.
O'Connor, J.
Kavanaugh, A.
Ruderman, E.
Curtis, J. R.
Ritchlin, C. T.
van der Heijde, D.
Solomon, D.
Greenberg, J. D.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1289 - 1290
[44] Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Mease, Philip
Liu, Mei
Rebello, Sabrina
McLean, Robert
Dube, Blessing
Glynn, Meghan
Yi, Esther
Park, Yujin
Ogdie, Alexis
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[45] CHARACTERIZATION OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS BY PRESENCE OF ENTHESITIS: DATA FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY
Mease, Philip J.
Liu, Mei
Rebello, Sabrina
Hua, Winnie
Mclean, Robert
Yi, Esther
Park, Yujin
Ogdie, Alexis
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1249 - 1250
[46] COMPARISON OF MEN AND WOMEN WITH AXIAL SPONDYLOARTHRITIS IN THE US-BASED CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY
Mease, Philip J.
Liu, Mei
Rebello, Sabrina
Mclean, Robert
Dube, Blessing
Glynn, Meghan
Yi, Esther
Park, Yujin
Ogdie, Alexis
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1230 - 1231
[47] Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease
Alexis Ogdie
Soumya D. Chakravarty
Natalie J. Shiff
Iris Lin
Robert R. McLean
Wendi Malley
Rebecca L. Spitzer
Arthur Kavanaugh
Joseph F. Merola
Drugs - Real World Outcomes, 2022, 9 : 617 - 628
[48] Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
Ogdie, Alexis
Middaugh, Nicole
Blachley, Taylor
Bourgeois, Tran
Ling, You-Li
Mundayat, Rajiv
Fallon, Lara
Masri, Karim
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1187 - 1190
[49] Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Mease, Philip J.
Ogdie, Alexis
Chakravarty, Soumya D.
Shiff, Natalie J.
Lin, Iris
McLean, Robert R.
Malley, Wendi
Spitzer, Rebecca L.
Kavanaugh, Arthur
Merola, Joseph F.
DRUGS-REAL WORLD OUTCOMES, 2022, 9 (04) : 617 - 628
[50] Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Ogdie, Alexis
Liu, Mei
Rebello, Sabrina
Cronin, Angel
Dube, Blessing
McLean, Robert
Yi, Esther
Hur, Peter
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2019, 71

← 1 2 3 4 5 →